Santhera Pharmaceuticals Holding Stock Net Income
| SPHDF Stock | USD 9.42 0.00 0.00% |
Santhera Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Santhera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Santhera Pink Sheet. The fundamental analysis module provides a way to measure Santhera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Santhera Pharmaceuticals pink sheet.
Santhera |
Santhera Pharmaceuticals Holding Company Net Income Analysis
Santhera Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Santhera Pharmaceuticals Net Income | (55.53 M) |
Most of Santhera Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Santhera Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Santhera Pharmaceuticals Holding reported net income of (55.53 Million). This is 116.27% lower than that of the Healthcare sector and 179.27% lower than that of the Biotechnology industry. The net income for all United States stocks is 109.72% higher than that of the company.
Santhera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Santhera Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Santhera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Santhera Pharmaceuticals by comparing valuation metrics of similar companies.Santhera Pharmaceuticals is currently under evaluation in net income category among its peers.
Santhera Fundamentals
| Return On Equity | -13.16 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (386.18) % | |||
| Current Valuation | 60.45 M | |||
| Shares Outstanding | 61.81 M | |||
| Shares Owned By Insiders | 18.77 % | |||
| Shares Owned By Institutions | 3.50 % | |||
| Price To Earning | (6.80) X | |||
| Price To Book | 2.75 X | |||
| Price To Sales | 469.19 X | |||
| Revenue | (1.59 M) | |||
| Gross Profit | (5.36 M) | |||
| EBITDA | (34.57 M) | |||
| Net Income | (55.53 M) | |||
| Cash And Equivalents | 21.21 M | |||
| Cash Per Share | 0.43 X | |||
| Total Debt | 25.8 M | |||
| Current Ratio | 0.75 X | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (37.36 M) | |||
| Earnings Per Share | (1.68) X | |||
| Number Of Employees | 39 | |||
| Beta | 0.8 | |||
| Market Capitalization | 74.18 M | |||
| Total Asset | 91.12 M | |||
| Retained Earnings | (291 M) | |||
| Working Capital | 64 M | |||
| Current Asset | 74 M | |||
| Current Liabilities | 10 M | |||
| Z Score | -3.0 | |||
| Net Asset | 91.12 M |
About Santhera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Santhera Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Santhera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Santhera Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Santhera Pink Sheet
Santhera Pharmaceuticals financial ratios help investors to determine whether Santhera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santhera with respect to the benefits of owning Santhera Pharmaceuticals security.